Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 5/20 | 0.51 |
| ▸ | AGER | Q15109 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8724213 | 0.92 | CNR2 (0.50) | GLACNR2AGERMAPTMCOLN3 | |
| SCHEMBL5935090 | 0.85 | CNR2 (0.57) | GLACNR2AGERMAPTMCOLN3 | |
| SCHEMBL8213964 | 0.83 | CNR2 (0.55) | GLACNR2AGERMAPTMCOLN3 | |
| Ditolamide SCHEMBL2110790 | 0.82 | CA9 (0.64) | GLACNR2CA12CA2CA9 | |
| SCHEMBL2362509 | 0.81 | GLA (0.56) | GLACNR2AGERMAPTMCOLN3 | |
| SCHEMBL398044 | 0.81 | CNR2 (0.57) | GLACNR2AGERMAPTMCOLN3 | |
| SCHEMBL898459 | 0.81 | GLA (0.56) | GLACNR2AGERMAPTMCOLN3 | |
| SCHEMBL218536 | 0.81 | SMN1; SMN2 (0.68) | GLACNR2MAPTMCOLN3CA12 | |
| SCHEMBL15177296 | 0.79 | SMN1; SMN2 (0.66) | GLACNR2MAPTMCOLN3CA12 | |
| SCHEMBL11711049 | 0.79 | SMN1; SMN2 (0.56) | GLACNR2MAPTMCOLN3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9125955-B2 | 99mTc imaging agents and methods of use | GENERAL ELECTRIC COMPANY (US) | 2015-09-08 | — | — | US | disclosed |
| US-9125955-B2 | 99mTc imaging agents and methods of use | GENERAL ELECTRIC COMPANY (US) | 2015-09-08 | — | — | US | disclosed |
| US-9125955-B2 | 99mTc imaging agents and methods of use | GENERAL ELECTRIC COMPANY (US) | 2015-09-08 | — | — | US | disclosed |
| EP-2809355-A2 | CHELATING AGENTS | General Electric Company (US) | 2014-12-10 | — | — | EP | disclosed |
| US-20140065065-A1 | 99mTc IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140065065-A1 | 99mTc IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140065065-A1 | 99mTc IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2013113801-A2 | CHELATING AGENTS | GENERAL ELECTRIC COMPANY (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013113801-A2 | CHELATING AGENTS | GENERAL ELECTRIC COMPANY (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20130195756-A1 | 99mTc IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130195756-A1 | 99mTc IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130195756-A1 | 99mTc IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2011073371-A1 | MANGANESE CHELATES AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING (MRI) | GE HEALTHCARE AS (NO) | 2011-06-23 | — | — | WO | disclosed |
| EP-0830351-A1 | PROCESS FOR PREPARING SUBSTITUTED POLYAZAMACROCYCLES | MONSANTO COMPANY (US) | 1998-03-25 | — | — | EP | disclosed |
| US-5721361-A | CONTACTING A DIAMINE OR TRIAMINE AND A DICARBOXYLIC ACID OR ESTER IN THE PRESENCE OF A BASE AND SOLVENT; COUPLING AGENT; REDUCTION; COMPLEXING WITH MANGANESE COMPOUNDS; ION EXCHANGING | THE MONSANTO COMPANY (US) | 1998-02-24 | — | — | US | disclosed |
| WO-1996040658-A1 | PROCESS FOR PREPARING SUBSTITUTED POLYAZAMACROCYCLES | MONSANTO COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130195756-A1 | 99mTc IMAGING AGENTS AND METHODS OF USE | SSTR3, CCR2, CX3CR1 | GLA 1444/4885CNR2 43/4885AGER 1996/4885 |
| US-20140065065-A1 | 99mTc IMAGING AGENTS AND METHODS OF USE | SSTR3, CX3CR1, CCR2 | GLA 2035/4885CNR2 63/4885AGER 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.